HC Wainwright Analysts Raise Earnings Estimates for RANI

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – HC Wainwright lifted their Q2 2026 EPS estimates for Rani Therapeutics in a research report issued on Monday, June 1st. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.05) per share for the quarter, up from their previous estimate of ($0.07). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Rani Therapeutics’ current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for Rani Therapeutics’ Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at ($0.25) EPS and FY2030 earnings at ($0.20) EPS.

Rani Therapeutics (NASDAQ:RANI) last released its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $1.71 million during the quarter, compared to analysts’ expectations of $1.13 million.

RANI has been the subject of several other reports. Canaccord Genuity Group reissued a “buy” rating and set a $5.00 price objective on shares of Rani Therapeutics in a report on Wednesday, May 20th. Wall Street Zen upgraded Rani Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Lake Street Capital started coverage on Rani Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $9.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Rani Therapeutics in a report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rani Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Rani Therapeutics Trading Down 4.2%

NASDAQ:RANI opened at $0.86 on Wednesday. Rani Therapeutics has a 12 month low of $0.39 and a 12 month high of $3.87. The firm’s 50 day moving average is $0.94 and its 200 day moving average is $1.25. The stock has a market capitalization of $106.25 million, a PE ratio of -2.09 and a beta of 0.74.

Hedge Funds Weigh In On Rani Therapeutics

Several hedge funds have recently bought and sold shares of RANI. Jefferies Financial Group Inc. bought a new stake in Rani Therapeutics during the 4th quarter worth approximately $40,000. Virtu Financial LLC purchased a new position in shares of Rani Therapeutics during the 4th quarter valued at $69,000. OMERS ADMINISTRATION Corp bought a new position in shares of Rani Therapeutics in the fourth quarter worth $93,000. Farallon Capital Management LLC bought a new position in shares of Rani Therapeutics in the fourth quarter worth $105,000. Finally, Kestra Private Wealth Services LLC raised its position in shares of Rani Therapeutics by 44.8% in the third quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company’s stock worth $113,000 after buying an additional 70,002 shares in the last quarter. Hedge funds and other institutional investors own 30.19% of the company’s stock.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.